STAT's Jason Mast reported on September 17, 2026 that the FDA on Thursday approved a new gene therapy for Sanfilippo syndrome type A, an ultra-rare disease sometimes known as childhood Alzheimer's. Named STAT coverage said the therapy, called Fayuvi, was developed by Ultragenyx, that it is the first drug specifically approved to treat Sanfilippo, and that Ultragenyx did not immediately release a price. Cara O'Neill, chief science officer of the Cure Sanfilippo Foundation, told STAT that families receiving the diagnosis would be given hope and an action plan for treatment rather than being told to take their kids home and love them. The FDA said it approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA. Acting FDA Commissioner Kyle Diamantas called it a historic moment. CBER Director Karim Mikhail called it a meaningful step forward. Megha Kaushal of the Office of Therapeutic Products cited meaningful neurodevelopmental benefit from a single intravenous dose. Named FDA coverage said Fayuvi is a one-time intravenous AAV9 gene therapy that delivers a working SGSH gene so cells can produce sulfamidase and reduce heparan sulfate buildup. An open-label, single-arm, multicenter study in patients ages 2 to 5 found treated patients maintained or improved cognitive function versus an untreated historical control. Common adverse reactions in more than 5 percent included AST increases, nausea and vomiting, fever, decreased appetite, decreased white blood cell and platelet counts, and increased amylase. Named FDA warnings include thrombotic microangiopathy and a potential long-term tumor risk from genome integration. Patients receive corticosteroids from one day before infusion through at least eight weeks after. Fayuvi received Orphan, Fast Track, and Breakthrough designations. BioSpace's Tristan Manalac reported a Jefferies wholesale acquisition cost of $3.95 million, shipping within 30 to 60 days, an indication for preserved neurodevelopmental function, a July 2025 manufacturing rejection then resubmission, about 3,000 to 5,000 treatable patients in commercially accessible geographies, and peak-sales estimates around $250 million. Unfinished FDA approval plus unfinished access price and shipping clocks is real. It is not already childhood dementia cured forever, and it is not already every eligible patient treated forever.
That is unfinished approval timing stacked on unfinished payer-and-price clocks and unfinished 30-to-60-day shipping. It is not a finished forever childhood-dementia cure certificate, and it is not a finished forever every-patient-treated lock.
## What They Reported
Named STAT, FDA, and BioSpace journalism described an unfinished FDA approval plus unfinished access, price, and shipping clocks, not a finished forever childhood-dementia cure and not a finished forever treated census of every eligible patient. STAT recorded Thursday approval of Fayuvi as the first Sanfilippo-specific drug, sometimes known as childhood Alzheimer's, Ultragenyx's decision not to immediately release a price, and Cara O'Neill's hope-and-action-plan language. The FDA recorded one-time intravenous AAV9 SGSH delivery, an open-label ages 2-5 cognitive study versus an untreated historical control, TMA and potential tumor warnings, and Orphan, Fast Track, and Breakthrough designations. BioSpace's Tristan Manalac added the $3.95 million Jefferies wholesale figure, the 30-to-60-day shipping window, the preserved-neurodevelopmental-function indication, the July 2025 manufacturing complete response letter then resubmission, about 3,000 to 5,000 treatable patients in commercially accessible geographies. Named coverage published unfinished approval plus unfinished access clocks. It did not publish that childhood dementia was already cured forever, and it did not publish that every eligible patient was already treated forever.
Social feeds often compress first-ever gene-therapy approval into childhood dementia already cured forever, or compress first-treatment language into every eligible patient already treated forever. Both habits flatten unfinished indication, price, shipping, and safety clocks.
## The Correction
Three corrections are required at once.
First, treating Thursday's FDA approval and maintained-or-improved cognitive scores in ages 2-5 as proof childhood dementia is already cured forever invents a finished forever cure certificate from unfinished single-arm evidence and unfinished safety clocks. Named FDA coverage compared treated patients with an untreated historical control in an open-label study. That is unfinished divergence from expected plateau and decline, not a finished forever dementia-reversal lock. Diamantas' historic-moment language and Mikhail's meaningful-step-forward language are unfinished first-treatment language. TMA risk, potential long-term tumor risk, and the corticosteroid window remain open. Unfinished FDA approval is not already childhood dementia cured forever.
Second, treating first-drug language, 3,000-to-5,000 patient estimates, and a shipping plan as proof every eligible patient is already treated forever invents a finished forever access census from unfinished commercial clocks. STAT recorded that Ultragenyx did not immediately release a price. BioSpace later cited a $3.95 million wholesale acquisition cost and a 30-to-60-day shipping window. Named BioSpace coverage said the therapy is indicated for patients with preserved neurodevelopmental function, not for every person ever diagnosed. A July 2025 manufacturing complete response letter then resubmission is unfinished quality-system history, not a finished forever treated lock. Unfinished access price and shipping clocks are not already every eligible patient treated forever.
Third, collapsing Cara O'Neill's hope-and-action-plan language, FDA historic-moment language, and BioSpace price figures into one forever meme invents either childhood dementia already cured forever or every eligible patient already treated forever. Accurate language keeps approval, indication limits, price, shipping, safety warnings, and finished forever cure-or-treated claims in separate sentences.
## Why This Matters
Gene-therapy approval headlines travel faster than the difference between an unfinished FDA authorization and a finished forever meme that childhood dementia is already cured, and faster than the difference between unfinished price and 30-to-60-day shipping clocks and a finished forever claim that every eligible patient is already treated.
False already-childhood-dementia-cured-forever claims invent finished forever disease reversal while historical-control evidence and TMA and tumor warnings remain open. False already-every-eligible-patient-treated-forever claims invent finished forever access from unfinished wholesale price, unfinished shipping, and a preserved-function indication.
NewsCorrections health rule: unfinished FDA approval plus unfinished access price and shipping clocks is not already childhood dementia cured forever and not already every eligible patient treated forever.
## Key Takeaways
- September 17, 2026: STAT's Jason Mast reported FDA approval of Ultragenyx's Fayuvi, the first drug specifically approved to treat Sanfilippo syndrome type A; Ultragenyx did not immediately release a price. - Named voice: Cure Sanfilippo Foundation chief science officer Cara O'Neill said families would get hope and an action plan for treatment, not only take-them-home-and-love-them instructions. - FDA: Fayuvi (rebisufligene etisparvovec-hopf) is a one-time IV AAV9 SGSH gene therapy; ages 2-5 cognitive scores maintained or improved versus an untreated historical control; Orphan, Fast Track, and Breakthrough designations. - Safety: common adverse reactions above 5 percent include AST increases, nausea and vomiting, fever, decreased appetite, and low blood counts; TMA risk; potential long-term tumor risk; corticosteroids at least eight weeks. - BioSpace/Jefferies: $3.95 million wholesale acquisition cost; ship in 30 to 60 days; preserved neurodevelopmental function indication; July 2025 manufacturing complete response letter then resubmission; about 3,000 to 5,000 treatable patients in commercially accessible geographies. - Unfinished FDA approval plus unfinished access price and shipping clocks is not already childhood dementia cured forever and not already every eligible patient treated forever.
